2021
DOI: 10.3892/etm.2021.11044
|View full text |Cite
|
Sign up to set email alerts
|

Treatment of patients with Covid‑19 with a high dose of ulinastatin

Abstract: Currently, there are no specific therapeutic agents available for the treatment of coronavirus disease 2019 . The present study aimed to assess the efficacy of high-dose ulinastatin for the treatment of patients with Covid-19. A total of 12 patients hospitalized with confirmed severe acute respiratory syndrome coronavirus 2 infection were treated with a high dose of ulinastatin alongside standard care. Changes in clinical manifestations, laboratory examinations and chest images were retrospectively analyzed. A… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
3
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 9 publications
(4 citation statements)
references
References 29 publications
1
3
0
Order By: Relevance
“…The massive use of azithromycin and vitamins in our study is attributed to guidance from the first edition of Uganda national guidelines for COVID-19 management recommending their use even for mild-moderate disease [ 35 ]. The frequent use of ulinastatin in our study could be supported by studies that reported some studies that reported some benefits, especially for COVID-19 patients with sepsis, or moderate-severe disease [ 36 , 37 ]. Our agreement is that clinicians should follow updated guidelines by their respective health authorities/organization while accounting for the evolving data on the safety and efficacy of various therapeutic agents.…”
Section: Discussionsupporting
confidence: 67%
“…The massive use of azithromycin and vitamins in our study is attributed to guidance from the first edition of Uganda national guidelines for COVID-19 management recommending their use even for mild-moderate disease [ 35 ]. The frequent use of ulinastatin in our study could be supported by studies that reported some studies that reported some benefits, especially for COVID-19 patients with sepsis, or moderate-severe disease [ 36 , 37 ]. Our agreement is that clinicians should follow updated guidelines by their respective health authorities/organization while accounting for the evolving data on the safety and efficacy of various therapeutic agents.…”
Section: Discussionsupporting
confidence: 67%
“…The standard dosage of UTI was 100,000 U once to three times per day. However, there is a few evidence that large dose UTI can have additional benefits ( 14 , 15 ). Blood samples of 2 ml were drawn on day 1, 3 and 5 after hospital admission and processed within 6 hours.…”
Section: Methodsmentioning
confidence: 99%
“…Upadacitinib, a selective JAK1/3 inhibitor for the treatment of severe RA, inhibits IL‐6, GM‐CSF, and IFN‐γ production and has anti‐inflammatory potential for COVID‐19, and currently has one clinical trial registration (NCT04393311). 276 , 277 Nezulcitinib is an inhaled pan‐JAK inhibitor that has recently been reported to have good therapeutic potential in respiratory tract injury and COVID‐19. 278 , 279 Currently, there is one clinical study (NCT05091723) registered on its treatment of COVID‐19 acute lung injury.…”
Section: Intervention Therapymentioning
confidence: 99%
“…Pacritinib, a JAK2 inhibitor, has been studied in prevention studies in critical COVID‐19 patients with or without cancer (NCT04404361). Upadacitinib, a selective JAK1/3 inhibitor for the treatment of severe RA, inhibits IL‐6, GM‐CSF, and IFN‐γ production and has anti‐inflammatory potential for COVID‐19, and currently has one clinical trial registration (NCT04393311) 276,277 . Nezulcitinib is an inhaled pan‐JAK inhibitor that has recently been reported to have good therapeutic potential in respiratory tract injury and COVID‐19 278,279 .…”
Section: Intervention Therapymentioning
confidence: 99%